Audited Financial Results for the Quarter and Year ended March 31, 2026.
LINCOLN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Lincoln Pharmaceuticals reported FY26 revenue from operations of Rs. 671.03 crore, up 7.7% from Rs. 623.23 crore in FY25. Total income reached Rs. 704.48 crore with 9.1% growth. Net profit for the year was Rs. 87.89 crore, up 6.74% from Rs. 82.35 crore. EBITDA stood at Rs. 131.14 crore with 5.78% growth. EPS improved to Rs. 43.88 per share from Rs. 41.11. The board recommended a dividend of Rs. 1.80 per share (18%). Statutory auditors issued an unmodified (clean) audit opinion. The company targets Rs. 1,000 crore revenue in 3 years with 15-18% annual growth, driven by cardiac, diabetic, dermatology, and ENT segments.
The stock shows steady growth with consistent profitability improvement and shareholder returns. However, EBITDA margins compressed slightly from 19.2% to 18.6%, and Q4 net profit growth was marginal at 0.52%. The clean audit and dividend announcement are positive signals for investors.